ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0476

Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High

Andrea Hemmig1, Markus Aschwanden2, Sabine Seiler1, Christoph Berger3, Philipp Köhn1, Noemi Mensch1, Daniel Staub2, Mihaela Stegert1, Stephan Imfeld2 and Thomas Daikeler1, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, 2Department of Angiology, University Hospital Basel, Basel, Switzerland, 3Departments of Dermatology, Rheumatology and Internal Medicine, University Center for Immunology, University Hospital Basel, Basel, Switzerland

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Permanent vision loss (PVL) remains the most feared complication of giant cell arteritis (GCA). In recent years, fast track clinic approaches for early GCA diagnosis have been described to reduce the incidence of PVL (1). We aim to examine patient and referral characteristics and trends in the incidence of PVL over the past 15 years.

Methods: Retrospective analysis of a longitudinal cohort of patients with suspected GCA treated at the University Hospital Basel between December 2006 and May 2021. We analyzed demographic data, symptoms, laboratory and imaging findings, and treatment. Time from first symptom to vision loss, to first physician contact and to steroid initiation was assessed. Only patients who were followed for at least 6 months after GCA diagnosis were included. PVL was defined as persisting complete or partial vision loss in at least one eye.

Results: The cohort includes 740 patients with suspicion of GCA. Of those, 311 patients were newly diagnosed with GCA. 282 (mean age 72.9 ± 8.3 years, 64% females) fulfilled inclusion criteria. Among these, 47 patients (17%) developed PVL. In 43 (91%) patients, PVL manifested at GCA diagnosis whereas in 4 (9%) patients, PVL developed more than one month after diagnosis (median time from GCA diagnosis to first visual symptom 59.5 days (IQR 42.3-90.5 days)). AION was the most common cause of PVL (Table 1). Characteristics of patients with and without PVL are similar to previous reports (Table 2). Patients with PVL were older, had more frequent hypertension, diabetes, and jaw claudication. Polymyalgia symptoms at diagnosis were less frequent among PVL patients. The incidence of PVL over 15 years remained constant (Figure 1).

Of the patients who developed PVL, the majority sought first medical contact because of new-onset visual symptoms (n=40, 85%). However, 27 (57%) patients with PVL reported having other cranial or systemic symptoms before the onset of visual manifestations with a median time from first symptom until first contact with their general practitioners (GP) of 21.0 days (IQR 9.5-31 days). The median time from first GP contact until steroid initiation was 0.0 days (IQR 0-1 days) in all patients who developed PVL.

Conclusion: In most patients, PVL manifested at diagnosis and only few cases developed PVL while being under treatment. Known risk factors for arteriosclerosis are significantly associated with PVL in our cohort. Despite immediate initiation of steroid treatment after first GP contact, incidence of PVL at GCA diagnosis does not decline since 2006, because in most patients PVL manifests before the first contact with GPs. However, more than half of the patients with PVL reported GCA symptoms other than ocular, which occurred a median of 25.0 days before the onset of visual disturbances. Thus, earlier diagnosis and treatment is possible. Education of patients and public as well as training of GPs is needed to shorten the time from first GCA associated symptom to start of treatment and hence to reduce the frequency of PVL.

References:
1. Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse. Front Med (Lausanne). 2020;7:589794.

Supporting image 1

Supporting image 2

Supporting image 3

Figure 1: Incidence of PVL over the last 15 years.


Disclosures: A. Hemmig, None; M. Aschwanden, None; S. Seiler, None; C. Berger, None; P. Köhn, None; N. Mensch, None; D. Staub, None; M. Stegert, None; S. Imfeld, None; T. Daikeler, None.

To cite this abstract in AMA style:

Hemmig A, Aschwanden M, Seiler S, Berger C, Köhn P, Mensch N, Staub D, Stegert M, Imfeld S, Daikeler T. Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/permanent-vision-loss-in-giant-cell-arteritis-why-the-incidence-remains-high/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/permanent-vision-loss-in-giant-cell-arteritis-why-the-incidence-remains-high/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology